Zoetis Inc. (NYSE:ZTS) Shares Acquired by Duality Advisers LP

Duality Advisers LP grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 43.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,641 shares of the company’s stock after acquiring an additional 12,359 shares during the period. Zoetis comprises approximately 0.7% of Duality Advisers LP’s holdings, making the stock its 3rd biggest position. Duality Advisers LP’s holdings in Zoetis were worth $6,877,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Peak Financial Advisors LLC acquired a new position in shares of Zoetis in the 4th quarter worth approximately $2,776,000. Focus Financial Network Inc. ADV purchased a new position in shares of Zoetis in the fourth quarter worth approximately $2,159,000. Price T Rowe Associates Inc. MD increased its position in shares of Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after acquiring an additional 3,244,074 shares in the last quarter. Ninety One UK Ltd increased its position in shares of Zoetis by 13.1% in the fourth quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after acquiring an additional 12,537 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its position in shares of Zoetis by 10.9% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after acquiring an additional 17,976 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Barclays decreased their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. HSBC dropped their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. The Goldman Sachs Group lowered their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. Stifel Nicolaus lowered their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $211.75.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at $2,237,316. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by company insiders.

Zoetis Trading Up 1.0 %

Zoetis stock traded up $1.82 during trading hours on Friday, reaching $179.56. 895,443 shares of the company’s stock traded hands, compared to its average volume of 2,884,955. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a market capitalization of $81.93 billion, a price-to-earnings ratio of 34.56, a PEG ratio of 2.69 and a beta of 0.86. The firm’s 50 day moving average is $172.13 and its 200-day moving average is $177.49.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.31 EPS. On average, analysts predict that Zoetis Inc. will post 5.76 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.96%. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.